Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership
AuthorHerrington, David M.
Sanders, John W.
Wierzba, Thomas F.
Bertoni, Alain G.
Seals, Austin L.
Runyon, Michael S.
McCurdy, Lewis H.
Gibbs, Michael A.
Friedman-Klabanoff, De Anna
JournalBMC Infectious Diseases
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractBackground: Estimating population prevalence and incidence of prior SARS-CoV-2 infection is essential to formulate public health recommendations concerning the COVID-19 pandemic. However, interpreting estimates based on sero-surveillance requires an understanding of the duration of elevated antibodies following SARS-CoV-2 infection, especially in the large number of people with pauci-symptomatic or asymptomatic disease. Methods: We examined > 30,000 serology assays for SARS-CoV-2 specific IgG and IgM assays acquired longitudinally in 11,468 adults between April and November 2020 in the COVID-19 Community Research Partnership. Results: Among participants with serologic evidence for infection but few or no symptoms or clinical disease, roughly 50% sero-reverted in 30 days of their initial positive test. Sero-reversion occurred more quickly for IgM than IgG and for antibodies targeting nucleocapsid protein compared with spike proteins, but was not associated with age, sex, race/ethnicity, or healthcare worker status. Conclusions: The short duration of antibody response suggests that the true population prevalence of prior SARS-CoV-2 infection may be significantly higher than presumed based on earlier sero-surveillance studies. The impact of the large number of minimally symptomatic COVID-19 cases with only a brief antibody response on population immunity remains to be determined.
SponsorsU.S. Department of Health and Human Services
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16744
- [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]
- Authors: Alessi D, Borré S, Barale A, Isabella A, Milano F, Rossi MA, Silano V, Piu N, Cena T, Faggiano F, Gruppo di Lavoro Fondazione Valsesia.
- Issue date: 2020 Sep-Dec
- From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany).
- Authors: Radon K, Bakuli A, Pütz P, Le Gleut R, Guggenbuehl Noller JM, Olbrich L, Saathoff E, Garí M, Schälte Y, Frahnow T, Wölfel R, Pritsch M, Rothe C, Pletschette M, Rubio-Acero R, Beyerl J, Metaxa D, Forster F, Thiel V, Castelletti N, Rieß F, Diefenbach MN, Fröschl G, Bruger J, Winter S, Frese J, Puchinger K, Brand I, Kroidl I, Wieser A, Hoelscher M, Hasenauer J, Fuchs C, KoCo19 study group.
- Issue date: 2021 Sep 8
- From Multiplex Serology to Serolomics-A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome.
- Authors: Butt J, Murugan R, Hippchen T, Olberg S, van Straaten M, Wardemann H, Stebbins E, Kräusslich HG, Bartenschlager R, Brenner H, Laketa V, Schöttker B, Müller B, Merle U, Waterboer T
- Issue date: 2021 Apr 24
- Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
- Authors: Dickson E, Palmateer NE, Murray J, Robertson C, Waugh C, Wallace LA, Mathie L, Heatlie K, Mavin S, Gousias P, Von Wissman B, Goldberg DJ, McAuley A
- Issue date: 2021 Jan
- IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays.
- Authors: Shah J, Liu S, Potula HH, Bhargava P, Cruz I, Force D, Bazerbashi A, Ramasamy R
- Issue date: 2021 Apr 7